Robert Harrington to Rosuvastatin Calcium
This is a "connection" page, showing publications Robert Harrington has written about Rosuvastatin Calcium.
Connection Strength
0.029
-
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
Score: 0.029